Theme: Inherited and Acquired Platelet Function Disorders Options A. Bernard–Soulier syndrome B. Glanzmann thrombasthenia C. Scott syndrome D. Wiskott–Aldrich syndrome E. Hermansky–Pudlak syndrome F. Chediak–Higashi syndrome G. Gray platelet syndrome H. Paris–Trousseau syndrome I. Aspirin-induced platelet dysfunction J. BTK inhibitor-associated platelet dysfunction K. SSRI-induced platelet dysfunction L. Platelet dysfunction secondary to paraproteinaemia M. Platelet dysfuncti

EMQ Theme: Managing transfusion investigations in patients receiving monoclonal antibody therapies Option List A. Perform testing using DTT-treated reagent red cells B. Provide K-negative red cells unless patient is known to be K-positive C. Refer sample to NHSBT Red Cell Immunohaematology laboratory D. Use Capture methodology E. Extended red cell genotyping F. Group O red cells for transfusion G. Perform alloadsorption studies H. Inform transfusion laboratory before therapy

Theme: Measurable Residual Disease (MRD) Monitoring in AML Options A. qPCR for NPM1 mutation B. qPCR for RUNX1::RUNX1T1 C. qPCR for CBFB::MYH11 D. qPCR for PML::RARA E. Multiparameter flow cytometry (MFC) F. FLT3-ITD ultra-high sensitivity NGS G. Bone marrow (BM) preferred over peripheral blood (PB) H. Peripheral blood (PB) acceptable if blasts ≥20% I. MRD monitoring not routinely recommended after 2 cycles J. Post-allogeneic transplant MRD surveillance Questions 1. A 42-year

Options A. Acute portal vein thrombosis B. Chronic portal vein thrombosis with portal cavernoma C. Budd–Chiari syndrome D. Acute mesenteric vein thrombosis E. Splenic vein thrombosis F. Myeloproliferative neoplasm-associated SVT G. Paroxysmal nocturnal haemoglobinuria (PNH) H. Cirrhosis-associated portal vein thrombosis I. Antiphospholipid syndrome-associated SVT J. Intestinal infarction secondary to SVT K. JAK2 V617F mutation-associated SVT L. Factor V Leiden-associated SVT

Option List A. Brentuximab vedotin monotherapy B. Brentuximab vedotin + bendamustine C. Brentuximab vedotin + nivolumab D. Brentuximab vedotin maintenance post-ASCT E. GDP chemotherapy F. High-dose therapy with autologous stem cell transplantation (ASCT) G. Immediate allogeneic stem cell transplantation H. Nivolumab monotherapy I. Observation only J. Pembrolizumab-GVD K. Peripheral neuropathy is a major toxicity of BV maintenance L. PET-negative status before ASCT predicts su

Theme: Investigation and Management of Antiphospholipid Syndrome (APS) Options A. Triple-positive antiphospholipid syndrome B. Catastrophic antiphospholipid syndrome (CAPS) C. Direct oral anticoagulant interference causing false-positive lupus anticoagulant D. Warfarin with target INR 2.0–3.0 E. Warfarin with target INR 3.0–4.0 F. Dual antiplatelet therapy G. Repeat antiphospholipid antibody testing after ≥12 weeks H. Lupus anticoagulant testing should be deferred I....

OPTIONS A. Hydroxyurea B. Azacitidine C. Decitabine + venetoclax D. Allogeneic stem cell transplantation E. Ruxolitinib F. Watch and wait G. Erythropoietin-stimulating agent H. Tagraxofusp I. Acute monocytic AML J. Oligomonocytic CMML K. CMML-1, dysplastic type L. CMML-2, proliferative type M. Reactive monocytosis N. VEXAS syndrome-associated CMML O. CPSSmol high-risk disease P. SF3B1-mutated CMML with ring sideroblasts Q. Therapy-related CMML R. HMA failure with clonal evolu

Theme: Acute Myeloid Leukaemia (AML) Options A. DA 3+7 plus Gemtuzumab Ozogamicin (GO) B. DA 3+10 plus Midostaurin C. CPX-351 (Vyxeos) D. FLAG-IDA E. ATRA + Arsenic Trioxide F. ATRA + Idarubicin (AIDA) G. Allogeneic stem cell transplantation in CR1 H. Gilteritinib I. Quizartinib J. Azacitidine + Donor Lymphocyte Infusion (DLI) K. HiDAC consolidation alone L. Hydroxycarbamide cytoreduction followed by induction M. Supportive/palliative management N. Enasidenib O. Ivosidenib Qu

Theme: Diagnosis, Risk Stratification and Management of ET Options A. Reactive thrombocytosis secondary to iron deficiency B. Triple-negative ET C. CALR-mutated ET D. JAK2 V617F-positive ET E. MPL-mutated ET F. Hydroxycarbamide G. Pegylated interferon-alpha H. Anagrelide I. Aspirin alone with observation J. Bone marrow biopsy and extended molecular testing K. Busulfan L. Essential thrombocythaemia in pregnancy requiring LMWH and interferon M. Idiopathic thrombocytosis of unde